Table 2.
Main features of COVID-19 vaccines. From ref. [2, [9], [10], [11], 18, 19] and www.clinicaltrials.gov.
| Vaccine | Developer | Platform | Doses | Efficacy** |
|---|---|---|---|---|
| BNT162b2* | Pfizer/BioNTech | mRNA | 2 (3 weeks apart) | 95% |
| mRNA-1273* | Moderna | mRNA | 2 (4 weeks apart) | 94% |
| Ad26.COV2.S* | Janssen/Johnson &Johnson | DNA Adenovirus vector | 1 | 67% |
| CVnCoV | CureVAC | mRNA | 2 (4 weeks apart) | NA |
| ChAdOx1nCoV-19* | AstraZeneca/University of Oxford/Serum Institute of India | DNA Adenovirus vector | 2 (4/8 to 12 weeks apart) | 70% |
| NVX-CoV2373 | Novavax | Recombinant protein | 2 (3 weeks apart) | 89% |
| Gam-COVID-Vac (Sputnik V) | Gamaleya Institute | DNA Adenovirus vectors | 2 (3 weeks apart) | 92% |
Legend: *= vaccines authorised for use in the European Union (https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines); **= efficacy against symptomatic/moderate/severe COVID-19 (see references for details); mRNA=messenger ribonucleic acid.